AWM
PCRX icon

Avior Wealth Management’s Pacira BioSciences PCRX Stock Holding History

Avior Wealth Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9
Closed -$262 – 3293
2024
Q1 		$262 Buy
+9
New +$276 ﹤0.01% 2773
2018
Q2 		– Sell
-2,365
Closed -$74K – 838
2018
Q1 		$74K Sell
2,365
-1,380
-37% -$49.1K 0.02% 462
2017
Q4 		$171K Buy
+3,745
New +$148K 0.04% 365

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Avior Wealth Management's PCRX Position: Q2 2024 in Review

Avior Wealth Management sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 9 shares — an estimated $262 sold.

Avior Wealth Management first reported a position in PCRX in Q4 2017 and held it in 3 quarters. The position peaked at $171K in Q4 2017. 282 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

  • Avior Wealth Management reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 9 Pacira BioSciences shares in Q2 2024, an estimated $262.
  • Avior Wealth Management first reported a position in Pacira BioSciences in Q4 2017 and held it in 3 quarters.
  • Avior Wealth Management's Pacira BioSciences position peaked at $171K in Q4 2017.
  • 282 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.